Generics Bulletin Explains: Removing Interchangeability Information From US Biosimilar Labels
Biosimilars Industry Backs Latest FDA Labeling Guidance – But Originators Disagree
A clear divide between the biosimilars sector and the brand industry has been demonstrated by responses to a consultation over FDA draft guidance recommending that biosimilar labels remove information on interchangeability. Generics Bulletin explains the opposing positions.
